Evidence map›Paper›PMID 42552419›Full record

ArticleMolecular psychiatry2026

The association of schizophrenia polygenic scores with continuously-hospitalized, treatment-resistant schizophrenia.

Urmi Das, James J Crowley, Robert Karlsson, Yi Lu, Michael O'Donovan, James T R Walters, Michael Didriksen, Richard Josiassen, Patrick F Sullivan, Kaarina Kowalec

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Urmi DasCollege of Pharmacy, University of Manitoba, Winnipeg, MB, Canada.ORCID http://orcid.org/0000-0001-7639-6521
James J CrowleyDepartments of Genetics and Psychiatry, University of North Carolina, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-9051-1557
Robert KarlssonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-8949-2587
Yi LuDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-9933-3654
Michael O'DonovanCentre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0001-7073-2379
James T R WaltersCentre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0002-6980-4053
Michael DidriksenDivision of Neuroscience, H. Lundbeck A/S, Valby, Denmark.
Richard Josiassen *Translational Neuroscience, LLC, Philadelphia, PA, USA.
Patrick F Sullivan *Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Kaarina Kowalec *College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada. Kaarina.kowalec@ki.se.ORCID http://orcid.org/0000-0003-3928-9879

Funding

A Trans-Nordic Study of Extreme Major DepressionR01MH123724 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PATRICK F SULLIVAN, Lu Yi · 2020 to 2026
$4.7M
RCUK | Medical Research Council (MRC) MR/Y004094/1U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01 MH123724Vetenskapsrådet (Swedish Research Council) D0886501
6 · The paper itself

Abstract

More than 20% of individuals with schizophrenia show minimal or no response to antipsychotic medications and little is known about genetic contributions to more severe forms of illness. This study sought to explore if cases with continuously-hospitalized, treatment-resistant schizophrenia (CH-TRS) carry a higher burden of common genetic variants compared to less severe forms. CH-TRS cases were recruited from Pennsylvania state psychiatric hospitals in the USA, with ≥ 5 years of continuous hospitalization, active treatment, and non-response to ≥ 3 antipsychotic medications. Three comparator groups were obtained from cohorts in the USA, Sweden, and the UK including TRS, general schizophrenia and non-psychiatric controls. Polygenic scores (PGS) of schizophrenia and cognitive ability were generated in individuals of European and African ancestry. Logistic regression assessed the association of PGS and CH-TRS cases (vs. comparators), with sex differences and sensitivity analyses excluding individuals with other diagnoses conducted to assess robustness. We included 18,571 individuals of European ancestry (346 CH-TRS, 10,757 TRS, 1148 general schizophrenia, 6320 non-psychiatric controls) and exploratory analyses of 476 individuals of African ancestry (78 CH-TRS, 398 non-psychiatric controls). For each standard deviation increase in the schizophrenia PGS, the odds of CH-TRS among individuals of European ancestry increased by 40-80% compared to general schizophrenia and TRS. Results in African ancestry participants mirrored those of European ancestry albeit with reduced levels of significance. Sex interactions and sensitivity analyses did not materially alter the estimates. This study demonstrates a greater burden of common genetic variants is associated with more severe forms of illness in schizophrenia.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.